ethambutol has been researched along with Opportunistic Infections in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costard-Jäckle, A; Meyer, S; Sattinger, E | 1 |
| Leung, KT; Siu, YP; Tong, MK; Yung, CY | 1 |
| Banks, J; Campbell, IA; Gelder, CM; Jenkins, PA; Prescott, RJ; Smith, AP | 1 |
| Heginbothom, ML; Magee, JT | 1 |
| Ormerod, P | 1 |
| Heginbothom, ML | 1 |
| Bollet, C; de Lamballerie, X; de Micco, P; Gevaudan, MJ; Mallet, MN; Sambuc, R | 1 |
| Dautzenberg, B; Grosset, J; Katlama, C; Mignon, A; Parrot, R; Perronne, C; Rozenbaum, W; Truffot, C | 1 |
3 trial(s) available for ethambutol and Opportunistic Infections
| Article | Year |
|---|---|
Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Ethambutol; Female; Humans; Immunotherapy; Male; Middle Aged; Opportunistic Infections; Rifampin; Tuberculosis, Pulmonary | 2008 |
First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; HIV Seronegativity; Humans; Isoniazid; Male; Middle Aged; Mycobacterium avium; Mycobacterium avium Complex; Mycobacterium Infections, Nontuberculous; Mycobacterium xenopi; Opportunistic Infections; Prospective Studies; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2001 |
Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Male; Mycobacterium Infections; Opportunistic Infections; Prospective Studies; Rifabutin; Rifamycins | 1991 |
6 other study(ies) available for ethambutol and Opportunistic Infections
| Article | Year |
|---|---|
Cutaneous tuberculosis mimicking erysipelas of the lower leg in a heart transplant recipient.
Topics: Antitubercular Agents; Erysipelas; Ethambutol; Heart Transplantation; Humans; Isoniazid; Leg; Opportunistic Infections; Pyrazinamide; Tuberculosis, Cutaneous | 2011 |
Successful kidney re-transplantation in a patient with previous allograft kidney tuberculosis.
Topics: Adult; Antitubercular Agents; Ethambutol; Humans; Immunosuppression Therapy; Isoniazid; Kidney Transplantation; Male; Opportunistic Infections; Pyrazinamide; Reoperation; Rifampin; Tuberculosis, Renal | 2004 |
Pyrolysis mass spectrometry: a predictor of clinical response to treatment in pulmonary opportunist mycobacterial infection: preliminary work with M. malmoense.
Topics: Ethambutol; Humans; Lung Diseases; Mass Spectrometry; Microbial Sensitivity Tests; Mycobacterium Infections; Opportunistic Infections; Rifampin | 1997 |
A step forward in the evidence-based treatment of opportunist mycobacteria.
Topics: Antibiotics, Antitubercular; Ethambutol; Evidence-Based Medicine; Humans; Mycobacterium Infections; Opportunistic Infections; Practice Guidelines as Topic; Rifampin; United Kingdom | 2001 |
The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
Topics: Antitubercular Agents; Ethambutol; Humans; In Vitro Techniques; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium Infections; Opportunistic Infections; Predictive Value of Tests; Rifampin; Treatment Outcome | 2001 |
[Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Mycobacterium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections; Opportunistic Infections; Quinolones; Rifabutin; Rifamycins | 1992 |